PDE4 and PDE5 inhibitors show great promise as therapeutic agents for neurological disorders like epilepsy, ischemia, TBI, and Alzheimer’s disease. The gene discussed is PDE4A; the disease is early-onset autosomal dominant Alzheimer disease.